title: Catalyzing the Critical Path Initiative: FDA's progress in drug development activities.
abstract: The US Food and Drug Administration (FDA) has directed considerable effort towards modernizing its regulatory processes over the past decade to address the challenges in the drug development sector. Through partnerships and input from stakeholders, multiple initiatives are under way, many projects have been launched, several have resulted in tangible results, and many are ongoing and under discussion. We are learning that collaborative efforts can better inform and leverage existing knowledge, that the challenges of data sharing and intellectual property can be overcome, and that there is wide interest in partnering to address key public health regulatory science issues. It is crucial that we continue to build on these initial efforts to facilitate drug development.
authors: Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
authors: A
authors: A
authors: Parekh
authors: S
authors: S
authors: Buckman-Garner
authors: S
authors: S
authors: McCune
authors: R
authors: R
authors: ONeill
authors: M
authors: M
authors: Geanacopoulos
authors: S
authors: S
authors: Amur
authors: C
authors: C
authors: Clingman
authors: R
authors: R
authors: Barratt
authors: M
authors: M
authors: Rocca
authors: I
authors: I
authors: Hills
authors: J
authors: J
authors: Woodcock
mesh_terms: D017277:Drug Approval; D055808:Drug Discovery / Q000331:legislation & jurisprudence / Q000639:trends*; D006801:Humans; D062069:Inventions / Q000639:trends; D055818:Public-Private Sector Partnerships; D014481:United States; D014486:United States Food and Drug Administration / Q000639:trends*